Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial

SIMPLE SUMMARY: The clinical application of PARPis in patients with ovarian cancer has unresolved issues, and whether PARPis can have a similar first-line efficacy to that of platinum-based chemotherapy is still undefined. This study used the PDX model to explore the above problems. We demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiayu, Li, Yan, Wang, Haiyuan, Li, Ting, Gu, Yu, Wang, Wei, Shan, Ying, Yin, Jie, Wang, Yongxue, Qin, Meng, Li, Siyi, Pan, Lingya, Peng, Siying, Jin, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563731/
https://www.ncbi.nlm.nih.gov/pubmed/36230574
http://dx.doi.org/10.3390/cancers14194649

Ejemplares similares

Ejemplares similares